Posted by Michael Wonder on 28 Jun 2018
Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as monotherapy to treat partial-onset seizures in adults with epilepsy
27 June 2018 - Aptiom now provides a once-daily monotherapy treatment option for adults with partial-onset seizures.
Sunovion Pharmaceuticals announced today that Health Canada has approved the use of Aptiom (eslicarbazepine acetate) as monotherapy for partial-onset seizures in adults with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy.
The approval is supported by data from a Phase 3, double-blind, active controlled, non-inferiority study in which Aptiom met its primary efficacy endpoint of non-inferiority to the active comparator, carbamazepine controlled release.
